Acomplia

0.0

More buying options:

Acomplia is a weight loss drug designed to aid individuals struggling with obesity. Acomplia is the first drug in a new type of weight-loss class known as “Cannabinoid-1 Receptor Blockers.” When taken as directed, Acomplia essentially blocks receptors in the brain in order to decrease appetite and control cravings. With this support, consumers are able to lose weight more effectively.

How Does Acomplia Work?

As Acomplia is classified as a “Cannabinoid-1 Receptor Blocker,” or CB1, it works by selectively blocking CB1 receptors in the brain and in peripheral organs. Once these CB1 receptors are blocked, Acomplia works by actively decreasing the over-activity of body systems that control energy balance, fat storage, metabolism, and weight. Most Acomplia users experience significant weight loss in the first 9 months of use, and most consumers report that the weight loss remained stable for two years after taking the drug.

Am I Eligible for Acomplia?

Individuals interested in taking Acomplia must first meet with a physician, as this weight loss drug is only available by prescription. To be approved for Acomplia, individuals must have a Body Mass Index greater than 30. While Acomplia is primarily intended to help individuals succeed with weight loss, this drug is also used to treat conditions such as:

Type 2 diabetes
Abnormal levels of fat in the blood
To prevent the risks of cardiovascular disease
To aid patients with a significantly large waist circumference

Acomplia and Smoking

In addition to providing consumers with weight loss benefits, Acomplia has also been utilized to support individuals who are struggling to quit smoking. A one-year study of Acomplia revealed that over 6,500 individuals were able to quit smoking while taking this drug.

Potential Cons of Acomplia

While Acomplia has been approved by the European Union since 2006, the United States Food and Drug Administration has not yet approved this drug. Furthermore, some users of Acomplia report experiences of negative side effects such as:

Nausea and vomiting
Upper respiratory tract infection
Upset stomach
Seeping disorders
Nervousness
Depression
Dizziness
Diarrhea
Itching
Excessive sweating
Muscle cramps
Fatigue
Bruising and tendonitis
Back pain
Memory loss and hot flashes

Clinical and Trial Studies of Acomplia

Clinical trials and studies have been conducted in over 6,800 consumers of Acomplia. All trial members were considered to be obese or overweight, and also suffered from additional conditions such as hypertension or dyslipidaemia. In these students, approximately 80% were women, and 20% were men. Over the course of a year, the average Acomplia consumer lost almost 14.5 pounds, compared to individuals who only lost approximately 3.5 pounds while taking a placebo.

Overall, the studies report: